Aleglitazar, a new, potent, and balanced dual PPAR@a/@c agonist for the treatment of type II diabetes
Design, synthesis, and SAR of novel @a-alkoxy-@b-arylpropionic acids as potent and balanced PPAR@a@c coagonists are described. One representative thereof, Aleglitazar ((S)-2Aa), was chosen for clinical development. Its X-ray structure in complex with both receptors as well as its high efficacy in animal models of T2D and dyslipidemia are also presented.
Version: za2963e q8za8 q8zbc q8zce q8zde q8ze7 q8zf4 q8zg3